Several research has focused on molecular mutations, notably TERT promoter mutation and BRAFV600E, in the context of radioiodine-refractory differentiated thyroid carcinoma (DTC), offering critical insights into the genetic mechanisms driving treatment resistance. Here, TERT is linked to differentiated thyroid carcinoma.